UNSPSC 51385615: Aspirin glycine calcium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C9H7O4.C2H4NO2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NK259942HJ, chemically known as calcium, (glycinato)(salicylato)-, acetate (ester), but more generally known as aspirin glycine calcium, which bears US NIH Compound Identifier 30987. European Medicines Agency schedules aspirin glycine calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435.

Most nations, for tariff purposes, schedule aspirin glycine calcium under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].C(C(=O)[O-])N.[CA+2].

UNSPSC 51385615 Aspirin glycine calcium (Commodity) does not align with the actual work state and local governments are buying under this code in recent activity. The three most recent opportunities tagged to this code involve naloxone and drug-deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are aspirin glycine calcium formulations. The code shows a significant mismatch between its nominal scope and current procurement practice, suggesting either systematic miscoding or that the commodity is rarely purchased through state and local competitive solicitation.

Recent activity under this code comes from Seminole County, Florida (naloxone and drug deactivation systems via IFB), the Texas Health and Human Services Commission (pharmacy benefit program capabilities via RFI), and the Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local jurisdictions including Oregon (generic pharmaceuticals and OTC products via RFP). Geographic spread is limited to Florida, Texas, and Minnesota with cooperative purchasing reach. The Seminole County IFB (due July 26, 2023) sought 1,900 units of naloxone and 800 drug-deactivation systems annually with quarterly deliveries; the Texas HHS RFI (posted April 3, 2026) explored direct-to-manufacturer prescription contracting; and MMCAP's RFP (due March 26, 2026) established multiple contracts for generic pharmaceuticals through three authorized wholesalers with awards effective July 1, 2026. The mismatch between code definition and actual procurement means this category warrants careful review before pursuit — confirm with the issuing body that aspirin glycine calcium is the actual intended scope before preparing a response.